AKT inhibitor AZD5363 well tolerated, yielded partial response in some patients with advanced solid tumours

The investigational drug AZD5363, which has shown activity in preclinical studies, was well tolerated in two phase I studies, and patients with advanced solid tumours showed partial response and stable disease, according to data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. Read more here.